Canaccord raised the firm’s price target on Merit Medical (MMSI) to $99 from $93 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $108 from $103 at Baird
- Hold Rating for Merit Medical Systems Due to Pending Long-term Data and Pricing Challenges for WRAPSODY Stent
- Merit Medical price target lowered to $93 from $104 at Canaccord
- Merit Medical price target lowered to $95 from $103 at Wells Fargo
- Merit Medical Systems: Strategic Adjustments and Growth Potential Justify Buy Rating